SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Clemens John)
 

Sökning: WFRF:(Clemens John) > A randomized, place...

A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India.

Mahalanabis, Dilip (författare)
Lopez, Anna Lena (författare)
Sur, Dipika (författare)
visa fler...
Deen, Jacqueline (författare)
Manna, Byomkesh (författare)
Kanungo, Suman (författare)
von Seidlein, Lorenz (författare)
Carbis, Rodney (författare)
Han, Seung Hyun (författare)
Shin, Seong Hye (författare)
Attridge, Stephen (författare)
Rao, Raman (författare)
Holmgren, Jan, 1944 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för mikrobiologi och immunologi,Institute of Biomedicine, Department of Microbiology and Immunology
Clemens, John (författare)
Bhattacharya, Sujit K (författare)
visa färre...
 (creator_code:org_t)
2008-06-04
2008
Engelska.
Ingår i: PLoS ONE. - : Public Library of Science (PLoS). - 1932-6203. ; 3:6
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
Abstract Ämnesord
Stäng  
  • OBJECTIVES: An effective vaccine against cholera has been used for public health purposes in Vietnam since the 1990s. This vaccine was reformulated to meet WHO requirements. We assessed the safety and immunogenicity of the reformulated bivalent (Vibrio cholerae 01 and 0139) killed whole cell oral vaccine in a cholera endemic area in Kolkata, India. DESIGN: Double-blind, randomized, placebo controlled trial. SETTING: The trial was conducted in the clinical trial ward of the Infectious Diseases Hospital in Kolkata, India. PARTICIPANTS: The participants were 101 healthy adults (males and non-pregnant females) aged 18-40 years and 100 healthy children (males and non-pregnant females) aged 1-17 years. INTERVENTIONS: Participants were randomized to receive either the bivalent killed whole cell oral cholera vaccine or placebo (killed oral Escherichia coli K12). OUTCOME MEASURES: For safety: proportion of subjects with adverse events during the duration of study participation. For immunogenicity: Proportion of subjects who had a > or = 4-fold rise in serum vibriocidal antibody titers 14 days after the second dose of vaccine or placebo. RESULTS: Adverse reactions were observed with similar frequency among vaccine and placebo recipients in both age groups. Among adults 4% of vaccine and 8% of placebo recipients and among children 4% of vaccine and 2% of placebo recipients had at least one adverse event within 28 days of the first dose of the vaccine. Following immunization, 53% of adult and 80% of children vaccinees showed a > or = 4 fold rise in serum V. cholerae O1 vibriocidal antibody titers. A less pronounced response to V. cholerae O139 vibriocidal antibody titers post-immunization was noted among vaccinees. CONCLUSIONS: We found the vaccine to be safe and immunogenic in a cholera-endemic area in India. TRIAL REGISTRATION: ClinicalTrials.gov NCT00119197.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Mikrobiologi inom det medicinska området (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Microbiology in the medical area (hsv//eng)

Nyckelord

Administration
Oral
Adolescent
Adult
Child
Child
Preschool
Cholera
epidemiology
immunology
prevention & control
Cholera Vaccines
administration & dosage
immunology
Double-Blind Method
Endemic Diseases
prevention & control
Female
Humans
India
epidemiology
Infant
Male
Outcome Assessment (Health Care)
Placebos
Sample Size

Publikations- och innehållstyp

vet (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

  • PLoS ONE (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy